Bio-E-Gel Against Hot Flashes: Positive Phase III Clinical Trial Results
Filed in archive Drugs, Vaccines and Therapeutics on October 4, 2005
The Phase III clinical trials on Bio-E-Gel revealed that three doses of Bio-E-Gel significantly decrease the number of hot flashes in menopausal women. The bio-identical estradiol gel also produced low estradiol blood levels, had a good safety profile, with minimal application site irritation, a side effect associated with transdermal patches.
Bio-E-Gel(TM) utilizes Antares Pharma's proprietary Advanced Transdermal Delivery gel system to deliver the hormone estradiol through the skin. Antares Pharma has licensed its estradiol gel in its patented ATD� system to BioSante for North America, but retains all rights to develop, market and license its own estradiol ATD� gel products in Europe, Japan and other important markets.
Read more about the clinical trial here.
Tags: menopause hormone biotech clinical phase phase+clinical clinical+trial trial+results
Vote for Bio-E-Gel Against Hot Flashes: Positive Phase III Clinical Trial Results:
|
Rating: 6.00 out of 2 vote(s) cast.
|
Response from:
Maureen
(03/30/06 10:29am)
I heard this product is awesome for hot flashes. Does anyone know the dose of estrogen they are using for the trials
Response from:
Ruth
(03/30/06 8:05pm)
Hi Maureen. I tried to find out, but it must be a trade secret. Sorry.
| RSS |  |
 | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells